Journals / EMU Journal of Pharmaceutical Sciences / 2026 / Volume: 9 Issue: 1

Benzazole–Carboxamide Hybrids as Potent Antiproliferative Agents Against Breast Cancer Cells

Şule Gürsoy(ECZACILIK FAKÜLTESİ)
Ronak Haj Ersan(Cihan University-Duhok)
Ömer Faruk Çöl(GAZI UNIVERSITY)
Pages
—
Publication Date
2026-05-21
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings provide preliminary structure–activity insights and highlight benzazole–benzamide hybrids as promising scaffolds for further anticancer drug development.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Breast cancer remains a leading cause of cancer-related mortality worldwide, and the development of novel small-molecule agents with improved efficacy and selectivity is still urgently needed.
📊
Key Findings & Data:Although benzazole and benzamide scaffolds are individually recognized for their diverse pharmacological activities, systematic studies exploring hybrid N-(benzazol-2-yl) 4-substituted benzamide derivatives as antiproliferative agents against breast cancer are limited.
💡
Conclusion & Impact:These findings provide preliminary structure–activity insights and highlight benzazole–benzamide hybrids as promising scaffolds for further anticancer drug development.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Benzazole derivatives · synthesis · breast cancer

Abstract

Breast cancer remains a leading cause of cancer-related mortality worldwide, and the development of novel small-molecule agents with improved efficacy and selectivity is still urgently needed. Although benzazole and benzamide scaffolds are individually recognized for their diverse pharmacological activities, systematic studies exploring hybrid N-(benzazol-2-yl) 4-substituted benzamide derivatives as antiproliferative agents against breast cancer are limited. In this study, a series of N-(benzazol-2-yl)-4-substituted benzamide derivatives was synthesized and fully characterized by ¹H NMR, ¹³C NMR, and IR spectroscopy. The antiproliferative activities of the synthesized compounds were evaluated against the human breast cancer cell line MCF-7 and the normal fibroblast cell line L929 using the MTT assay. The compounds were obtained in good to excellent yields (70–85%). Several derivatives exhibited strong growth-inhibitory effects, with IC₅₀ values ranging from 3.11 to 12.39 µM. Among the tested molecules, compounds 6 and 11 demonstrated the most significant cytotoxic effects, and compound 6 emerged as the most promising candidate for further investigation. These findings provide preliminary structure–activity insights and highlight benzazole–benzamide hybrids as promising scaffolds for further anticancer drug development.

🔖

Cite This Article

Gürsoy, Ş., Ersan, R. H., Çöl, Ö. F. (2026). Benzazole–Carboxamide Hybrids as Potent Antiproliferative Agents Against Breast Cancer Cells. EMU Journal of Pharmaceutical Sciences, Volume: 9 Issue: 1. https://doi.org/10.54994/emujpharmsci.1838511

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Algul O, Ersan RH, Alagoz MA, Duran N, Burmaoglu S (2021). An efficient synthesis of novel di-heterocyclic benzazole derivatives and evaluation of their antiproliferative activities. J Biomol Struct Dyn 39(18): 6926-6938.
  2. Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, et al. (2023). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases 10(4): 1367-1401.
  3. Banmare S, Mude G (2023). Awareness regarding breast cancer among the female population in Wardha District. F1000Research 12: 1223.
  4. Burmaoglu S, Algul O, Anıl DA, Gobek A, Duran GG, et al. (2016). Synthesis and anti-proliferative activity of fluoro-substituted chalcones. Bioorg Med Chem Lett 26(13): 3172-3176.
  5. Cheong JE, Zaffagni M, Chung I, Xu Y, Wang Y, et al. (2018). Synthesis and anticancer activity of novel water soluble benzimidazole carbamates. Eur J Med Chem 144(2018): 372-385.
  6. Ersan RH, Alagoz MA, Ertan-Bolelli T, Duran N, Burmaoglu S, et al. (2021). Head-to-head bisbenzazole derivatives as antiproliferative agents: design, synthesis, in vitro activity, and SAR analysis. Molecular Diversity 25(4): 2247-2259.
  7. Gursoy S, Ozturk ES, Zoatier B, Ulger M, Algul O (2024). Synthesis and antitubercular activities of acetamide-substituted benzazole derivatives. Erzincan University Journal of Science and Technology 17(2): 474-487.
  8. Irfan A, Batool F, Zahra Naqvi SA, Islam A, Osman SM, et al. (2020). Benzothiazole derivatives as anticancer agents. J Enzyme Inhib Med Chem 35(1): 265-279.
  9. Kuzu B, Hepokur C, Alagoz MA, Burmaoglu S, Algul O (2022). Synthesis, biological evaluation and in silico studies of some 2‐substituted benzoxazole derivatives as potential anticancer agents to breast cancer. ChemistrySelect 7(1): e202103559.
  10. Kuzu B, Hepokur C, Turkmenoglu B, Burmaoglu S, Algul O (2022). Design, synthesis and in vitro antiproliferation activity of some 2-aryl and-heteroaryl benzoxazole derivatives. Future Med Chem 14(14): 1027-1048.
  11. Singh AK, Kumar A, Singh H, Sonawane P, Paliwal H, et al. (2022). Concept of hybrid drugs and recent advancements in anticancer hybrids. Pharmaceuticals 15(9): 1071.
  12. Singh V, Afshan T, Tyagi P, Varadwaj PK, Sahoo AK (2023). Recent development of multi-targeted inhibitors of human topoisomerase II enzyme as potent cancer therapeutics. Int J Biol Macromol 226: 473-484.
  13. Szumilak M, Anna WO, Andrzej S (2021). "Hybrid drugs—a strategy for overcoming anticancer drug resistance?." Molecules 26(9): 2601.
  14. Wilkinson L, Gathani T (2022). Understanding breast cancer as a global health concern. Br J Radiol 95(1130): 20211033.
  15. Yang F, He Q, Dai X, Zhang X, Song D (2023). The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies. Front Pharmacol 14: 1143102.
  16. Zoatier B, Gizem Yildiztekin K, Abdullah Alagoz M, Hepokur C, Burmaoglu S, Algul O (2025). Development of Potent Type V MAPK Inhibitors: Design, Synthesis, and Biological Evaluation of Benzothiazole Derivatives Targeting p38α MAPK in Breast Cancer Cells. Archiv der Pharmazie 358(4): e2500011.
  17. Zoatier B, Yildirim M, Alagoz MA, Yetkin D, Turkmenoglu B, et al. (2023). N-(benzazol-2-yl)-2-substituted phenylacetamide derivatives: Design, synthesis and biological evaluation against MCF7 breast cancer cell line. J Mol Struct 1285: 135513.
  18. Zoatier B, Yildiztekin G, Alagoz MA, Hepokur C, Dilek E, et al. (2025). Benzoxazole Derivatives as Dual p38α Mitogen‐Activated Protein Kinase and Acetylcholinesterase Inhibitors: Design, Synthesis, and Evaluation for Alzheimer's Disease and Cancer Therapy. ChemMedChem 20(22): e202500669.